Recent trials and meta-analyses have raised questions about choice of therapy and use of strict glycaemic targets
In August 2006, representatives of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) published a consensus algorithm for glycaemic management of type 2 diabetes.1 The algorithm provoked debate, but the authors defended their recommendations,2 including the introduction of metformin at diagnosis and the addition of insulin, sulfonylureas or glitazones as second-line therapy if satisfactory glycaemic control is not achieved. The glycaemic target at this and later stages of therapeutic intensification was a glycated haemoglobin (HbA1c) level less than 7.0%. However, based on epidemiological data from studies suggesting no threshold for microvascular or macrovascular benefit, including pooled results from the United Kingdom Prospective Diabetes Study (UKPDS),3 organisations such as the ADA suggested more stringent goals — including a normal HbA1c level (< 6.0%) — if the clinical situation allowed this.4
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
- 2. Ferrannini E. Response to comment on: Nathan DM, Buse JB, Davidson MB et al (2006). Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711–1721. Diabetologia 2007; 50: 1356-1357.
- 3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
- 4. American Diabetes Association. Standards of medical care in diabetes — 2006. Diabetes Care 2006; 29 Suppl 1: S4-S42.
- 5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
- 6. Takeda Pharmaceuticals North America Inc. Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone HOI) tablets for type 2 diabetes mellitus. http://www.fda.gov/medwaTCH/safety/2007/Actosmar0807.pdf (accessed May 2007).
- 7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
- 8. Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5: 116-120.
- 9. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; May 26 [Epub ahead of print].
- 10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 2008; 51: 8-11.
- 11. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
- 12. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
- 13. American Diabetes Association. Intense blood glucose control yields no significant effect on CVD reduction in VA Diabetes Trial [press release]. Alexandria, Va: ADA, 2008; 8 Jun. http://www.diabetes.org/for-media/pr-intense-blood-glucose-control-yields-no-significant-effect-on-cvd-reduction.jsp (accessed Jun 2008).
- 14. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
- 15. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med 2007; 357: 28-38.
- 16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
- 17. American Diabetes Association. Statement from the American Diabetes Association related to the ACCORD trial announcement [press release]. Alexandria, Va: ADA, 2008; 6 Feb. http://www.diabetes.org/for-media/pr-ada-statement-related-to-accord-trail-announcement-020608.jsp (accessed May 2008).
I have served on Advisory Boards for, and received speaker fees and travel assistance to attend meetings from, Eli Lilly (distributor of pioglitazone and exenatide), GlaxoSmithKline (manufacturer of rosiglitazone) and Merck Sharp and Dohme (manufacturer of sitagliptin). I have also received speaker fees and travel assistance to attend meetings from Alphapharm (manufacturer of metformin) and Servier Laboratories (manufacturer of gliclazide).